1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NCI SBIR/STTR Omnibus Grant Solicitations is sponsored by National Cancer Institute (NCI) - NIH. The NCI SBIR/STTR program offers grants for investigator-initiated projects within the NIH mission related to cancer technology development. While the primary focus is cancer, areas like digital health, technologies for cancer prevention, and behavioral health interventions are included.
A precision wellness healthtech for Black women could be relevant if it has a strong connection to cancer prevention, early detection, or improving outcomes for cancer disparities.
Get alerted about grants like this
Get emailed when new opportunities from “National Cancer Institute (NCI) - NIH” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses eligible for NIH SBIR/STTR programs. Confirm the full requirements in the official notice before applying.
The current listing shows award sizes ranging from $300,000 to $4.5 million, tailored to the stage of technology development. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NCI SBIR/STTR Omnibus Grant Solicitations are due September 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NCI SBIR/STTR Omnibus Grant Solicitations is funded by National Cancer Institute (NCI) - NIH. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
National Cancer Institute Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs is sponsored by National Cancer Institute (NCI) - NIH. The NCI SBIR and STTR programs support small businesses in developing innovative cancer technologies with strong potential to improve health outcomes. This includes therapeutics, diagnostics, imaging technologies, and tools for cancer biology research.
National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional) is sponsored by National Cancer Institute (NCI) - NIH. This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated Program Project (P01) applications addressing broad areas of cancer research, including cancer biology, prevention, diagnosis, treatment, and control. Applications must consist of at least three research projects and an Administrative Core, all sharing a common central theme.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
NIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read articleNIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read article